Regeneron Pharmaceuticals, Inc. (BVL:REGN)

Peru flag Peru · Delayed Price · Currency is PEN · Price in USD
750.80
0.00 (0.00%)
At close: Dec 5, 2025
-29.35%
Market Cap 249.00B
Revenue (ttm) 49.40B
Net Income (ttm) 15.87B
Shares Out n/a
EPS (ttm) 144.21
PE Ratio 15.69
Forward PE 15.74
Dividend 12.61 (1.68%)
Ex-Dividend Date Nov 20, 2025
Volume n/a
Average Volume 56
Open n/a
Previous Close 750.80
Day's Range n/a
52-Week Range 564.51 - 1,057.34
Beta n/a
RSI 93.05
Earnings Date Feb 3, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Pharmaceutical Preparations
Founded 1988
Employees 15,106
Stock Exchange Lima Stock Exchange
Ticker Symbol REGN
Full Company Profile

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD Financial Statements

News

There is no news available yet.